Issues in the future development of new analgesic drugsDavid-Pereira, Ana; Dickenson, Anthony H.Current Opinion in Supportive and Palliative Care: June 2019 - Volume 13 - Issue 2 - p 107–110 doi: 10.1097/SPC.0000000000000425 PAIN: NON-MALIGNANT DISEASES: Edited by Anthony H. Dickenson and Kirsty Bannister Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review There is a clear unmet need for either the development of new drugs for the treatment of painful pathologies or the better use of the existing agents denoted by the lack of efficacy of many existing drugs in a number of patients, limitations of their use due to severity of side effects, and by the high number of drugs that fail to reach clinical efficacy from preclinical development. This account considers the efforts being made to better validate new analgesic components and to improve translational efficacy of existing drugs. Recent findings A better use of the available models and tools can improve the predictive validity of new analgesic drugs, as well as using intermediate steps when translating drugs to clinical context such as characterizing drugs using stem cell-sensory derived neurones. Profiling patient sensory phenotypes can decrease the number of failed clinical trials and improve patient outcome. Summary An integrative approach, comprising the use of complementary techniques to fully characterize drug profiles, is necessary to improve translational success of new analgesics. Biosciences Division, Department of Neuroscience, Pharmacology and Physiology, University College London, London, UK Correspondence to Ana David-Pereira, PhD, Biosciences Division, Department of Neuroscience, Pharmacology and Physiology, University College London, Gower Street, London WC1E 6BT, UK. Tel: +44 207 679 3733; e-mail: firstname.lastname@example.org Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.